<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995835</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2021-0086</org_study_id>
    <nct_id>NCT04995835</nct_id>
  </id_info>
  <brief_title>Cefiderocol PK in Patients on ECMO</brief_title>
  <official_title>Ex Vivo Sequestration and Pharmacokinetics of Cefiderocol in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph L. Kuti, PharmD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shionogi Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life-support for&#xD;
      critically ill patients where blood is extracted from the vascular system and circulated by a&#xD;
      mechanical pump while it is oxygenated and reinfused into the patient's circulation. It is&#xD;
      well known that critically ill patients may experience alterations in antibiotic&#xD;
      pharmacokinetics, and as a result, dosing modifications are generally required. There is a&#xD;
      need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs.&#xD;
      This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic,&#xD;
      Cefiderocol, in critically ill patient receiving ECMO.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, Phase 1b, pharmacokinetic study of Cefiderocol in 8&#xD;
      critically ill patients receiving ECMO support at Hartford Hospital. Informed consent will be&#xD;
      collected from all study participants, legal authorized representative, or their next of kin&#xD;
      in order to participate. This is not a treatment study; all participants will receive other&#xD;
      antibiotics as necessary to treat any current infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">July 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cefiderocol Clearance</measure>
    <time_frame>8 hours</time_frame>
    <description>The Clearance in liters/hour of Cefiderocol from the plasma of critically ill patients receiving ECMO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cefiderocol Area Under the Curve (AUC)</measure>
    <time_frame>8 hours</time_frame>
    <description>The AUC in milligram*hour/liter of Cefiderocol calculated from concentrations collected between zero and 8 hours at steady-state.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Cefiderocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive four to six doses of Cefiderocol as per current prescribing information based on calculated creatinine clearance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefiderocol</intervention_name>
    <description>After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol</description>
    <arm_group_label>Cefiderocol</arm_group_label>
    <other_name>Fetroja</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  On support with veno-venous- or veno-arterial-ECMO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding&#xD;
&#xD;
          -  History of any moderate or severe hypersensitivity or allergic reaction to any&#xD;
             Î²-lactam antibiotic (a history of mild rash to a cephalosporin followed by uneventful&#xD;
             re-exposure is not a contraindication)&#xD;
&#xD;
          -  Receiving Cefiderocol to treat documented or suspected infection within 72 hours of&#xD;
             screening, or expected to receive Cefiderocol during the study intervention phase&#xD;
&#xD;
          -  Severe renal dysfunction defined as a CrCL &lt; 15 mL/min (as calculated by the Cockcroft&#xD;
             Gault equation using actual body weight) or requirement for continuous renal&#xD;
             replacement therapy or hemodialysis&#xD;
&#xD;
          -  A hemoglobin less than 8 gm/dl at baseline&#xD;
&#xD;
          -  Acute liver injury, defined as aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) &gt; 5 times the upper limit of normal, or AST or ALT &gt; 3 times&#xD;
             the upper limit of normal with an associated total bilirubin &gt; 2 times upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Any rapidly progressing disease or immediately life-threatening illness (defined as&#xD;
             imminent death within 48 hours in the opinion of the investigator)&#xD;
&#xD;
          -  Any condition or circumstance that, in the opinion of the investigator, would&#xD;
             compromise the safety of the patient or the quality of study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L Kuti, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph L Kuti, PharmD</last_name>
    <phone>8609723612</phone>
    <email>joseph.kuti@hhchealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Rubinstein</last_name>
    <phone>8609729290</phone>
    <email>Jamie.Rubinstein@hhchealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph L Kuti, PharmD</last_name>
      <phone>860-972-3612</phone>
      <email>joseph.kuti@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Jason A Gluck, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David P Nicolau, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomefa E Asempa, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Joseph L. Kuti, PharmD</investigator_full_name>
    <investigator_title>Associate Director, Center for Anti-Infective Research and Development</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>Cephalosporins</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

